Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

WCCT Global Inc

Neither a doctor nor a teaching hospital

Research payments

$9,892,150

76 payments

Through program year 2025, WCCT Global Inc is reported as receiving $9,892,150 in research payments, across 76 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $2,674,373 38
2023 Research $340 1
2021 Research $4,370,716 29
2020 Research $185,789 2
2019 Research $2,660,932 6

Breakdown

Who paid Research payments · program years 2019–2025
  1. Noven Pharmaceuticals, Inc. $3,676,436 26 payments
  2. Amgen Inc. $3,094,432 3 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $2,674,373 38 payments
  4. AbbVie, Inc. $346,405 2 payments
  5. Shire North American Group Inc $42,505 3 payments
  6. Regeneron Pharmaceuticals, Inc. $31,513 2 payments
  7. AstraZeneca Pharmaceuticals LP $26,146 1 payment
  8. Novartis Pharmaceuticals Corporation $340 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Multiple Dose, Open Label, Three-Treatment, Three-Period, Three-Way Crossover Study to Assess the Adhesion of Hp-5000 and the Relative Exposure of Hp-5000 Compared to Diclofenac Sodium Topical Solutin 1.5% and Diclofenac Sodium 75 MG Dr Tablet in Healthy Adult Subjects $2,689,665 15 payments
  2. A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Oral Doses of TAK-360 in Healthy Participants $2,674,373 38 payments
  3. AMG 145-A single dose relative bioavailability study $2,586,914 1 payment
  4. A Single-Center, Randomized, Single-Dose, Open-Label, Five-Period, Two-Way Crossover Study to Determine the Effect of External Heat, Exercise, Overlay and Water Exposure on the Pharmacokinetics of Hp-5000 in Healthy Adult Subjects $986,771 11 payments
  5. AMG 133 - Japanese Bridging Study $347,875 1 payment
  6. Assessment of Multiple-Dose Pharmacokinetics and Safety of the Co-administration of Galicaftor, Navocaftor and ABBV-111 and Potential of ABBV-111 for CYP3A Induction in Healthy Volunteers $346,405 2 payments
  7. AMG 145 - A single dose relative bioavailability study $159,643 1 payment
  8. Study of Shp639 Eye Drops in Adults With High Eye Pressure Or Primary Open-Angle Glaucoma $39,315 1 payment
  9. A Randomized, Placebo-Controlled, Parallel Panel Study to Assess the Effects of Regn3500, Dupilumab, and Combination of Regn3500 Plus Dupilumab on Markers of Inflammation After Bronchial Allergen Challenge in Patients With Allergic Asthma $31,513 2 payments
  10. A Phase 1-2a Clinical Study to Evaluate the Efficacy of MEDI8852 in the Treatment of Influenza in Adults Challenged with a Wild-Type Influenza Strain $26,146 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record